



**Pharmacy and Therapeutics Committee Decisions
November 06, 2015**

Type of Review	Drug/Therapeutic Class	P&T Decision												
New Medication	<p>Gaucher Disease</p> <p><u>Formulary status and number of unique members</u></p> <table border="1" data-bbox="426 753 1598 902"> <tr> <td>Cerdelga™ (eliglustat- Genzyme)</td> <td>NF</td> <td>0</td> </tr> <tr> <td>Vpriv® (velaglucerase alfa IV -Shire)</td> <td>NF</td> <td>0</td> </tr> <tr> <td>Elelyso® (taliglucerase alfa IV- Pfizer)</td> <td>NF</td> <td>0</td> </tr> <tr> <td>Zavesca® (miglustat-Actelion)</td> <td>NF</td> <td>0</td> </tr> </table>	Cerdelga™ (eliglustat- Genzyme)	NF	0	Vpriv® (velaglucerase alfa IV -Shire)	NF	0	Elelyso® (taliglucerase alfa IV- Pfizer)	NF	0	Zavesca® (miglustat-Actelion)	NF	0	Recommendation that Cerdelga to remain Non-Formulary with approved coverage criteria.
Cerdelga™ (eliglustat- Genzyme)	NF	0												
Vpriv® (velaglucerase alfa IV -Shire)	NF	0												
Elelyso® (taliglucerase alfa IV- Pfizer)	NF	0												
Zavesca® (miglustat-Actelion)	NF	0												
	<p>Cystic Fibrosis Transmembrane Regulators</p> <p><u>Formulary status and number of unique members</u></p> <table border="1" data-bbox="426 1182 1598 1263"> <tr> <td>Lumacifto/ivacaftor (Orkambi®- Vertex)</td> <td>NF</td> <td>4</td> </tr> <tr> <td>ivacaftor (Kalydeco® - Vertex)</td> <td>F [PA]</td> <td>2</td> </tr> </table>	Lumacifto/ivacaftor (Orkambi®- Vertex)	NF	4	ivacaftor (Kalydeco® - Vertex)	F [PA]	2	Recommend that Orkambi be laced on the formulary with prior authorization criteria to FDA approved indications (included).						
Lumacifto/ivacaftor (Orkambi®- Vertex)	NF	4												
ivacaftor (Kalydeco® - Vertex)	F [PA]	2												
	Treatment of idiopathic pulmonary fibrosis	DECISION:												

	<p><u>Formulary status and number of unique members</u></p> <table border="1"> <tr> <td data-bbox="426 305 1369 342">Esbriet[®] (pirfenidone capsules – InterMune)</td> <td data-bbox="1369 305 1486 342">NF</td> <td data-bbox="1486 305 1600 342">0</td> </tr> <tr> <td data-bbox="426 342 1369 380">Ofev[®] (nintedinib-Boehringer Ingelheim Pharmaceuticals)</td> <td data-bbox="1369 342 1486 380">NF</td> <td data-bbox="1486 342 1600 380">1</td> </tr> </table>	Esbriet [®] (pirfenidone capsules – InterMune)	NF	0	Ofev [®] (nintedinib-Boehringer Ingelheim Pharmaceuticals)	NF	1	<p>1. Maintain Esbriet as Non-formulary with addition of coverage criteria. 2. Update Non-formulary coverage criteria to include trial and failure of Esbriet if indicated as appropriate first-line therapy.</p>																														
Esbriet [®] (pirfenidone capsules – InterMune)	NF	0																																				
Ofev [®] (nintedinib-Boehringer Ingelheim Pharmaceuticals)	NF	1																																				
	<p>Angiotensin Receptor Blockers and Combinations</p> <table border="1"> <tr> <td data-bbox="426 673 1451 711">azilsartan (Edarbi[®] - Arbor Pharmaceuticals)</td> <td data-bbox="1451 673 1600 711">NF</td> </tr> <tr> <td data-bbox="426 711 1451 748">azilsartan/chlorthalidone (Edarbyclor[®] - Takeda)</td> <td data-bbox="1451 711 1600 748">NF</td> </tr> <tr> <td data-bbox="426 748 1451 786">candesartan (generics)</td> <td data-bbox="1451 748 1600 786">F-PA</td> </tr> <tr> <td data-bbox="426 786 1451 823">candesartan/hydrochlorothiazide (generics)</td> <td data-bbox="1451 786 1600 823">NF</td> </tr> <tr> <td data-bbox="426 823 1451 860">eprosartan (generics) (manufacturer d/c)</td> <td data-bbox="1451 823 1600 860">F</td> </tr> <tr> <td data-bbox="426 860 1451 898">eprosartan/hydrochlorothiazide (Teveten[®] HCT – Abbvie)</td> <td data-bbox="1451 860 1600 898">NF</td> </tr> <tr> <td data-bbox="426 898 1451 935">irbesartan (generics)</td> <td data-bbox="1451 898 1600 935">F-PA</td> </tr> <tr> <td data-bbox="426 935 1451 972">irbesartan/hydrochlorothiazide (generics)</td> <td data-bbox="1451 935 1600 972">NF</td> </tr> <tr> <td data-bbox="426 972 1451 1010">losartan (generics)</td> <td data-bbox="1451 972 1600 1010">F</td> </tr> <tr> <td data-bbox="426 1010 1451 1047">losartan/hydrochlorothiazide (generics)</td> <td data-bbox="1451 1010 1600 1047">F</td> </tr> <tr> <td data-bbox="426 1047 1451 1084">olmesartan (Benicar[®] – Sankyo)</td> <td data-bbox="1451 1047 1600 1084">F-PA</td> </tr> <tr> <td data-bbox="426 1084 1451 1122">olmesartan/hydrochlorothiazide (Benicar[®] HCT – Sankyo)</td> <td data-bbox="1451 1084 1600 1122">NF</td> </tr> <tr> <td data-bbox="426 1122 1451 1159">telmisartan (generics)</td> <td data-bbox="1451 1122 1600 1159">F-PA</td> </tr> <tr> <td data-bbox="426 1159 1451 1196">telmisartan/hydrochlorothiazide (generics)</td> <td data-bbox="1451 1159 1600 1196">NF</td> </tr> <tr> <td data-bbox="426 1196 1451 1234">valsartan (generics)</td> <td data-bbox="1451 1196 1600 1234">F -PA</td> </tr> <tr> <td data-bbox="426 1234 1451 1271">valsartan/hydrochlorothiazide (generics)</td> <td data-bbox="1451 1234 1600 1271">NF</td> </tr> <tr> <td data-bbox="426 1271 1451 1308">sacubitril/valsartan (Entresto[®] – Novartis)</td> <td data-bbox="1451 1271 1600 1308">NF</td> </tr> <tr> <td data-bbox="426 1308 1451 1346"></td> <td data-bbox="1451 1308 1600 1346"></td> </tr> </table>	azilsartan (Edarbi [®] - Arbor Pharmaceuticals)	NF	azilsartan/chlorthalidone (Edarbyclor [®] - Takeda)	NF	candesartan (generics)	F-PA	candesartan/hydrochlorothiazide (generics)	NF	eprosartan (generics) (manufacturer d/c)	F	eprosartan/hydrochlorothiazide (Teveten [®] HCT – Abbvie)	NF	irbesartan (generics)	F-PA	irbesartan/hydrochlorothiazide (generics)	NF	losartan (generics)	F	losartan/hydrochlorothiazide (generics)	F	olmesartan (Benicar [®] – Sankyo)	F-PA	olmesartan/hydrochlorothiazide (Benicar [®] HCT – Sankyo)	NF	telmisartan (generics)	F-PA	telmisartan/hydrochlorothiazide (generics)	NF	valsartan (generics)	F -PA	valsartan/hydrochlorothiazide (generics)	NF	sacubitril/valsartan (Entresto [®] – Novartis)	NF			<p>DECISION:</p> <p>1. Maintain Entresto as non-formulary with approved coverage criteria. 2. Remove prior authorization requirement for irbesartan and irbesartan/HCTZ.</p>
azilsartan (Edarbi [®] - Arbor Pharmaceuticals)	NF																																					
azilsartan/chlorthalidone (Edarbyclor [®] - Takeda)	NF																																					
candesartan (generics)	F-PA																																					
candesartan/hydrochlorothiazide (generics)	NF																																					
eprosartan (generics) (manufacturer d/c)	F																																					
eprosartan/hydrochlorothiazide (Teveten [®] HCT – Abbvie)	NF																																					
irbesartan (generics)	F-PA																																					
irbesartan/hydrochlorothiazide (generics)	NF																																					
losartan (generics)	F																																					
losartan/hydrochlorothiazide (generics)	F																																					
olmesartan (Benicar [®] – Sankyo)	F-PA																																					
olmesartan/hydrochlorothiazide (Benicar [®] HCT – Sankyo)	NF																																					
telmisartan (generics)	F-PA																																					
telmisartan/hydrochlorothiazide (generics)	NF																																					
valsartan (generics)	F -PA																																					
valsartan/hydrochlorothiazide (generics)	NF																																					
sacubitril/valsartan (Entresto [®] – Novartis)	NF																																					
	<p>PCSK9 Inhibitors</p> <p><u>Formulary status and number of unique members</u></p>	<p>DECISION: Maintain Non-formulary</p>																																				

	alirocumab (Praluent [®] - Sanofi/Regeneron)	NF	0	status of Repatha and Praluent with approved coverage criteria
	evolocumab (Repatha [®] - Amgen)	NF	0	
	bococizumab (Pfizer)	Expected: 2H:2016/1H:2017		
	LY3015014 (Lilly)	Expected: 2019		
Therapeutic Class Reviews	Biosimilars			P&T Recommendation Continue to monitor and review new biosimilars to promote the safe and effective use of cost-effective medications.
	Filgrastim-Sndz (Zarxio – Sandoz)	Neupogen	Approved	
	Infliximab (Remsima – Celltrion/Pfizer/Hospira)	Remicade	Pending (December 2015)	
	Pegfilgrastim (Neupeg – Apotex/Intas Pharmaceutical)	Neulasta	Pending	
	Epoetin Zeta (Retacrit-Hospira/Pfizer)	Epogen	Pending	
	ABP 980 (trastuzumab - Amgen)	Herceptin	Phase III	
	BCD 022 (trastuzumab - Biocad)	Herceptin	Phase III	
	PF05280014 (trastuzumab - Pfizer)	Herceptin	Phase III	
	HERMyl (trastuzumab - Mylan)	Herceptin	Phase III	

	SB3 (trastuzumab - Samsung Bioepis)	Herceptin	Phase III	
	ABP-215 (bevacizumab - Actavis)	Avastin	Phase III	
	BCD-021 (bevacizumab - Biocad)	Avastin	Phase III	
	BI 695502 (bevacizumab - Boehringer Ingelheim)	Avastin	Phase III	
	PF-06439535 (bevacizumab - Pfizer)	Avastin	Phase III	
	ABP-501 (adalimumab - Amgen)	Humira	Phase III	
	BI 695501 (adalimumab - Boehringer Ingelheim)	Humira	Phase III	
	CHS-1420 (adalimumab - Coherus)	Humira	Phase III	
	GP2017 (adalimumab - Sandoz)	Humira	Phase III	
	PF-06410293 (adalimumab - Pfizer)	Humira	Phase III	
	SB5 (adalimumab - Samsung Bioepis/Biogen)	Humira	Phase III	

	BOW015 (infliximab - Ranbaxy/Epirus)	Remicade	Phase III
	NI-071 (infliximab - Aprogen/Sanofi/Nichi-Iko)	Remicade	Phase III
	PF-06438179 (infliximab - Pfizer)	Remicade	Phase III
	SB2 (infliximab - Samsung Bioepis/Biogen)	Remicade	Phase III
	MYL-1401H (pegfilgrastim - Mylan)	Neulasta	Phase III
	Algeron (peginterferon alpha 2B - Biocad)	Peg-Intron	Phase III
	BCD-020 (rituximab - Biocad)	Rituxan	Phase III
	BI 695500 (rituximab - Boehringer Ingelheim)	Rituxan	Phase III
	CT-P10 (rituximab - Celltrion)	Rituxan	Phase III
	GP2013 (rituximab - Sandoz)	Rituxan	Phase III
	MabionCD20 (rituximab - Mabion)	Rituxan	Phase III

	PF-05280586 (rituximab - Pfizer)	Rituxan	Phase III				
	Filgrastim-Sndz (Zarxio – Sandoz)					DECISION: Move Zarxio to Formulary status with same prior authorization criteria as Neupogen.	
Decrease the incidence of infection, as manifested by febrile neutropenia in patients with nonmyeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a significant incidence of severe neutropenia with fever	X	X					
Reduce the time to neutrophil recovery and the duration of fever, following induction or consolidation chemotherapy treatment of patients with acute myeloid leukemia (AML)	X	X					
Reduce the duration of neutropenia and neutropenia-related clinical sequelae	X	X					
Mobilize autologous hematopoietic progenitor cells into the peripheral blood for collection by leukapheresis	X	X					
Reduce the incidence and duration of sequelae of severe neutropenia in symptomatic patients with congenital neutropenia, cyclic neutropenia, or idiopathic neutropenia	X	X					
Increase survival in patients acutely exposed to myelosuppressive doses of radiation		X					

	Decrease the duration of severe neutropenia in patients with nonmyeloid malignancies receiving myelosuppressive chemotherapy associated with a clinically significant incidence of neutropenic fever			X																						
	<p>Self-Injectable Epinephrine for Anaphylaxis</p> <p><u>Formulary Status and number of unique members</u></p> <table border="1"> <tr> <td>Auvi-QTM (epinephrine for injection – Sanofi)</td> <td>NF</td> <td>9</td> </tr> <tr> <td>EpiPen[®] 2-Pak (epinephrine for injection – Mylan Specialty)</td> <td>F</td> <td>2409</td> </tr> <tr> <td>EpiPen Jr.[®] 2-Pak (epinephrine for injection – Mylan Specialty)</td> <td>F</td> <td>1009</td> </tr> <tr> <td>Epinephrine for injection (0.15mg and 0.3mg) (Lineage Therapeutics)</td> <td>F</td> <td>286</td> </tr> <tr> <td>AdrenaClick[®] (epinephrine for injection - Amedra)</td> <td>NF</td> <td>0</td> </tr> <tr> <td>Adrenalin[®] (epinephrine for injection – JHP Pharmaceuticals)</td> <td>NF</td> <td>0</td> </tr> <tr> <td></td> <td></td> <td></td> </tr> </table>				Auvi-Q TM (epinephrine for injection – Sanofi)	NF	9	EpiPen [®] 2-Pak (epinephrine for injection – Mylan Specialty)	F	2409	EpiPen Jr. [®] 2-Pak (epinephrine for injection – Mylan Specialty)	F	1009	Epinephrine for injection (0.15mg and 0.3mg) (Lineage Therapeutics)	F	286	AdrenaClick [®] (epinephrine for injection - Amedra)	NF	0	Adrenalin [®] (epinephrine for injection – JHP Pharmaceuticals)	NF	0				<p>DECISION:</p> <p>1. Move brand name Epi-pen products to Non-formulary.</p> <p>2. Move generic epinephrine auto injectors (0.15 and 0.3mg) to formulary with no PA.</p>
Auvi-Q TM (epinephrine for injection – Sanofi)	NF	9																								
EpiPen [®] 2-Pak (epinephrine for injection – Mylan Specialty)	F	2409																								
EpiPen Jr. [®] 2-Pak (epinephrine for injection – Mylan Specialty)	F	1009																								
Epinephrine for injection (0.15mg and 0.3mg) (Lineage Therapeutics)	F	286																								
AdrenaClick [®] (epinephrine for injection - Amedra)	NF	0																								
Adrenalin [®] (epinephrine for injection – JHP Pharmaceuticals)	NF	0																								
	<p>Antiretrovirals (ARVs) for Human Immunodeficiency Virus</p> <table border="1"> <tr> <td rowspan="8">Protease Inhibitors</td> <td>atazanavir (Reyataz[®] – Bristol-Myers-Squibb)</td> <td>F</td> </tr> <tr> <td>darunavir (Prezista[®] – Tibotec)</td> <td>F</td> </tr> <tr> <td>fosamprenavir (Lexiva[®] – GlaxoSmithKline)</td> <td>F</td> </tr> <tr> <td>indinavir (Crixivan[®] – Merck)</td> <td>F</td> </tr> <tr> <td>nelfinavir (Viracept[®] – Pfizer)</td> <td>F</td> </tr> <tr> <td>ritonavir (Norvir[®] – Abbott)</td> <td>F</td> </tr> <tr> <td>saquinavir (Invirase[®] – Roche)</td> <td>F</td> </tr> <tr> <td>tipranavir (Aptivus[®] – Boehringer-Ingelheim)</td> <td>F</td> </tr> <tr> <td>Protease Inhibitor</td> <td>lopinavir/ritonavir (Kaletra[®] – Abbott)</td> <td>F</td> </tr> </table>				Protease Inhibitors	atazanavir (Reyataz [®] – Bristol-Myers-Squibb)	F	darunavir (Prezista [®] – Tibotec)	F	fosamprenavir (Lexiva [®] – GlaxoSmithKline)	F	indinavir (Crixivan [®] – Merck)	F	nelfinavir (Viracept [®] – Pfizer)	F	ritonavir (Norvir [®] – Abbott)	F	saquinavir (Invirase [®] – Roche)	F	tipranavir (Aptivus [®] – Boehringer-Ingelheim)	F	Protease Inhibitor	lopinavir/ritonavir (Kaletra [®] – Abbott)	F	<p>DECISION:</p> <p>1. Retain formulary status of all ARVs for HIV</p> <p>2. Move Tybost to formulary status with no PA required.</p>	
Protease Inhibitors	atazanavir (Reyataz [®] – Bristol-Myers-Squibb)	F																								
	darunavir (Prezista [®] – Tibotec)	F																								
	fosamprenavir (Lexiva [®] – GlaxoSmithKline)	F																								
	indinavir (Crixivan [®] – Merck)	F																								
	nelfinavir (Viracept [®] – Pfizer)	F																								
	ritonavir (Norvir [®] – Abbott)	F																								
	saquinavir (Invirase [®] – Roche)	F																								
	tipranavir (Aptivus [®] – Boehringer-Ingelheim)	F																								
Protease Inhibitor	lopinavir/ritonavir (Kaletra [®] – Abbott)	F																								

	Combinations		
	Nucleotide Analog Reverse Transcriptase Inhibitor	tenofovir (Viread [®] – Gilead)	F
	Nucleoside Reverse Transcriptase Inhibitors	abacavir (Ziagen [®] – GlaxoSmithKline)	F
		didanosine (Videx [®] Pediatric Solution – Bristol-Myers-Squibb)	F
		didanosine delayed-release (generics)	F
		emtricitabine (Emtriva [®] – Gilead)	F
		lamivudine (Epivir [®] – GlaxoSmithKline)	F
		stavudine (Zerit [®] – Bristol-Myers-Squibb)	F
		zidovudine (generics)	F
	Nucleoside Analog Reverse Transcriptase Inhibitor Combinations	abacavir/lamivudine (Epzicom [®] – GlaxoSmithKline)	F
		abacavir/lamivudine/zidovudine (Trizivir [®] – GlaxoSmithKline)	F
		emtricitabine/efavirenz/tenofovir (Atripla [®] – Gilead)	F
		emtricitabine/rilpivirine/tenofovir (Complera [®] – Gilead)	F
		emtricitabine/tenofovir (Truvada [®] – Gilead)	F
		lamivudine/zidovudine (Combivir [®] – GlaxoSmithKline)	F
	Non-Nucleoside Reverse Transcriptase Inhibitors	delavirdine (Rescriptor [®] – Pfizer)	F
		efavirenz (Sustiva [®] – Bristol-Myers-Squibb)	F
		etravirine (Intelence [®] – Tibotec Therapeutics)	F
		nevirapine (Viramune [®] – Boehringer-Ingelheim)	F
		rilpivirine (Edurant [®] – Tibotec Therapeutics)	F
	Fusion Inhibitors	enfuvirtide (Fuzeon [®] – Roche)	F
	Integrase Inhibitors	raltegravir (Isentress [®] – Merck)	F
		elvitegravir (Vitekta [®] – Gilead)	F
		dolutegravir (Tivicay [®] ViiV Healthcare/GlaxoSmithKline)	F

	CCR5 Antagonist	maraviroc (Selzentry [®] – Pfizer)	F	
	CYP3A Inhibitor (Booster agent- no antiretroviral activity)	cobicistat (Tybost [®] – Gilead)	NF	
	HMG-CoA Reductase Inhibitors			DECISION: Retain current formulary status for all HMG-CoA Reductase Inhibitors
	atorvastatin (generics)		F	
	fluvastatin (generics)		NF	
	fluvastatin extended-release (Lescol [®] XL – Novartis)		NF	
	lovastatin (generics)		F	
	lovastatin extended-release (Altoprev [®] – Andrx Labs)		NF	
	pitavastatin (Livalo [®] – Kowa/Lilly)		NF	
	pravastatin (generics)		F	
	rosuvastatin (Crestor [®] – AstraZeneca)		F [ST]	
	simvastatin (generics)		F	
	atorvastatin/amlodipine (generics)		NF	
	lovastatin/niacin (Advicor [®] – AbbVie)		NF	
	simvastatin/ezetimibe (Vytorin [®] – Merck)		NF	
	simvastatin/niacin (Simcor [®] – AbbVie)		NF	
	simvastatin/sitagliptin (Juvissync [®] – Merck)		NF	
	atorvastatin/ezetimibe (Liptruzet [™] – Merck)		NF	
	Anti-hypertriglyceridemia agents			DECISION: Retain current formulary status for all anti-hypertriglyceridemia, fibric acid agents.
	TriCor [®] (fenofibrate tablets – AbbVie, generic)		F	
	Lofibra [®] (fenofibrate tablets and capsules – Teva Select Brands)		NF	
	Antara [®] (fenofibrate capsules – Lupin Pharma, generic)		F	
	Triglide [®] (fenofibrate tablets – Shionogi)		NF	
	Lipofen [®] (fenofibrate capsules – Kowa Pharmaceuticals)		NF	
	Fenoglide [®] (fenofibrate tablets – Santarus)		NF	

	<table border="1"> <tr> <td>Trilipix[®] (fenofibric acid capsules, delayed release – AbbVie)</td> <td>NF</td> </tr> <tr> <td>Fibricor^{□□} (fenofibric acid tablets – AR Scientific/Mutual)</td> <td>NF</td> </tr> <tr> <td>fenofibrate capsules and tablets (generics – multiple manufacturers)</td> <td>F</td> </tr> <tr> <td>fenofibric acid capsules and tablets (generic – multiple manufacturers)</td> <td>F</td> </tr> <tr> <td>Lopid[®] (gemfibrozil tablets – Pfizer, generics)</td> <td>F</td> </tr> </table>	Trilipix [®] (fenofibric acid capsules, delayed release – AbbVie)	NF	Fibricor ^{□□} (fenofibric acid tablets – AR Scientific/Mutual)	NF	fenofibrate capsules and tablets (generics – multiple manufacturers)	F	fenofibric acid capsules and tablets (generic – multiple manufacturers)	F	Lopid [®] (gemfibrozil tablets – Pfizer, generics)	F																		
Trilipix [®] (fenofibric acid capsules, delayed release – AbbVie)	NF																												
Fibricor ^{□□} (fenofibric acid tablets – AR Scientific/Mutual)	NF																												
fenofibrate capsules and tablets (generics – multiple manufacturers)	F																												
fenofibric acid capsules and tablets (generic – multiple manufacturers)	F																												
Lopid [®] (gemfibrozil tablets – Pfizer, generics)	F																												
	<p>Bile Acid Sequestrants and dyslipidemia treatment medications</p> <table border="1"> <tr> <td>cholestyramine oral suspension (generics)</td> <td>F</td> </tr> <tr> <td>colestipol oral suspension & micronized tablets (generics)</td> <td>F</td> </tr> <tr> <td>colesevelam tablets (Welchol[®] – Daiichi-Sankyo)</td> <td>NF</td> </tr> <tr> <td>ezetimibe (Zetia[®] - Merck)</td> <td>NF</td> </tr> <tr> <td>niacin (Niaspan[®] - Abbot Laboratories)</td> <td>F</td> </tr> </table>	cholestyramine oral suspension (generics)	F	colestipol oral suspension & micronized tablets (generics)	F	colesevelam tablets (Welchol [®] – Daiichi-Sankyo)	NF	ezetimibe (Zetia [®] - Merck)	NF	niacin (Niaspan [®] - Abbot Laboratories)	F	DECISION: Retain current formulary status of all bile acid sequestrants and dyslipidemia treatment medications.																	
cholestyramine oral suspension (generics)	F																												
colestipol oral suspension & micronized tablets (generics)	F																												
colesevelam tablets (Welchol [®] – Daiichi-Sankyo)	NF																												
ezetimibe (Zetia [®] - Merck)	NF																												
niacin (Niaspan [®] - Abbot Laboratories)	F																												
	<p>Selective Serotonin Reuptake Inhibitors (SSRIs) and Related Agents</p> <p><u>Formulary status and number of unique members</u></p> <table border="1"> <tr> <td>vortioxetine (Brintellix[®] - Takeda)</td> <td>NF</td> <td>0</td> </tr> <tr> <td>paroxetine 7.5mg capsules (Brisdelle[®] - Noven Therapeutics)</td> <td>NF</td> <td>0</td> </tr> <tr> <td>paroxetine mesylate (Pexeva[®] - Noven Therapeutics)</td> <td>NF</td> <td>0</td> </tr> <tr> <td>vilazodone (Viibryd[®] - Merck/Trovis Pharmacueticals)</td> <td>NF</td> <td>10</td> </tr> <tr> <td>celexa (generics)</td> <td>F</td> <td>12973</td> </tr> <tr> <td>escitalopram (generics)</td> <td>F</td> <td>349</td> </tr> <tr> <td>fluoxetine (generics)</td> <td>F</td> <td>11193</td> </tr> <tr> <td>fluvoxamine (generics)</td> <td>F</td> <td>169</td> </tr> <tr> <td>paroxetine (generics)</td> <td>F</td> <td>3982</td> </tr> </table>	vortioxetine (Brintellix [®] - Takeda)	NF	0	paroxetine 7.5mg capsules (Brisdelle [®] - Noven Therapeutics)	NF	0	paroxetine mesylate (Pexeva [®] - Noven Therapeutics)	NF	0	vilazodone (Viibryd [®] - Merck/Trovis Pharmacueticals)	NF	10	celexa (generics)	F	12973	escitalopram (generics)	F	349	fluoxetine (generics)	F	11193	fluvoxamine (generics)	F	169	paroxetine (generics)	F	3982	<p>DECISION:</p> <ol style="list-style-type: none"> 1. Retain formulary status of all SSRIs. 2. Investigate possibility of adding step therapy requirement to fluvoxamine for unique indication.
vortioxetine (Brintellix [®] - Takeda)	NF	0																											
paroxetine 7.5mg capsules (Brisdelle [®] - Noven Therapeutics)	NF	0																											
paroxetine mesylate (Pexeva [®] - Noven Therapeutics)	NF	0																											
vilazodone (Viibryd [®] - Merck/Trovis Pharmacueticals)	NF	10																											
celexa (generics)	F	12973																											
escitalopram (generics)	F	349																											
fluoxetine (generics)	F	11193																											
fluvoxamine (generics)	F	169																											
paroxetine (generics)	F	3982																											

	paroxetine controlled release (Paxil®CR – Glaxo SmithKline)	NF	20	
	sertraline (generics)	F	13044	
	Serotonin and Norepinephrine Reuptake Inhibitors			DECISION: 1. Move venlafaxine ER tablets from formulary too non formulary and retain formulary status of ER capsules. 2. Retain current formulary status for all serotonin and norepinephrine reuptake inhibitors.
	Formulary status and number of unique members			
	levomilnacipran extended-release capsules (Fetzima® - Forest)	NF	0	
	desvenlafaxine succinate extended-release tablets (Pristiq® - Wyeth)	NF	30	
	duloxetine (Cymbalta® - Lilly)	F	3556	
	venlafaxine immediate-release (generics)	F	1834	
	venlafaxine extended-release (generics)	F	5549	
	Antivirals for Influenza			DECISION: Retain current formulary status of the influenza agents.
	Relenza® (zanamavir- GSK)	F		
	Tamiflu® (oseltamivir- Genetech)	F		
	Amantadine (generics)	F		
	Rimantidine (generics)	F		
	Oral Therapy for Inflammatory Bowel Syndrome and Ulcerative Colitis			DECISION: Retain current formulary status of the oral Inflammatory Bowel Syndrome and Ulcerative Colitis agents.
	Amitiza™ (lubiprostone- Takeda)	NF		
	Linzess® (linaclotide- Actavis)	F-PA		
	Apriso® (mesalamine- Salix)	NF		
	Asacol® (mesalamine-Actavis)	F		
	Asacol® HD (mesalamine-Actavis)	F		
	Azulfidine® (sulfasalazine- Pfizer)	NF		
	Azulfidine Entab® (sulfasalazine- Pfizer)	NF		

	Colazal [®] (balsalazide disodium –Salix)	NF	
	sulfasalazine (generic)	F	
	Delzicol [™] (mesalamine- Actavis)	F	
	balsalazide (generic)	F-PA	
	Dipentum ^{□□} (olsalazine- Alaven)	F	
	Giazo ^{□□} (balsalazide disodium –Salix)	F-PA	
	Lialda [®] (mesalamine- Shire)	NF	
	Pentasa [□] (mesalamine- Shire)	NF	

	<p>Ophthalmic Anti-Allergics</p> <table border="1"> <tr><td>alcaftadine (Lastacaft[®] - Allergan)</td><td>NF</td></tr> <tr><td>azelastine hydrochloride 0.05% (generics)</td><td>NF</td></tr> <tr><td>bepotastine besilate 1.5% (Bepreve[®] -ISTA Pharmaceuticals)</td><td>NF</td></tr> <tr><td>cromolyn sodium 4% (generics)</td><td>F</td></tr> <tr><td>emedastine difumarate 0.05% (Emadine[®] - Alcon)</td><td>NF</td></tr> <tr><td>epinastine hydrochloride 0.05% (Elestat[®] -Allergan/Inspire)</td><td>NF</td></tr> <tr><td>ketorolac tromethamine 0.5% (generics)(Acular[®] - Allergan)</td><td>F</td></tr> <tr><td>ketotifen fumarate 0.025% (generics)</td><td>F</td></tr> <tr><td>lodoxamide tromethamine 0.1% (Alomide[®] -Alcon)</td><td>NF</td></tr> <tr><td>loteprednol etabonate 0.2% (Alrex[®] - Bausch & Lomb)</td><td>NF</td></tr> <tr><td>nedocromil sodium 2% (Alocril[®] - Allergan)</td><td>NF</td></tr> <tr><td>olopatadine hydrochloride 0.1% (Patanol[®] - Alcon)</td><td>NF</td></tr> <tr><td>olopatadine hydrochloride 0.2% (Pataday[®] - Alcon)</td><td>NF</td></tr> <tr><td>pemirolast potassium 0.1% (Alamast[®] -Vistakon)</td><td>NF</td></tr> </table>	alcaftadine (Lastacaft [®] - Allergan)	NF	azelastine hydrochloride 0.05% (generics)	NF	bepotastine besilate 1.5% (Bepreve [®] -ISTA Pharmaceuticals)	NF	cromolyn sodium 4% (generics)	F	emedastine difumarate 0.05% (Emadine [®] - Alcon)	NF	epinastine hydrochloride 0.05% (Elestat [®] -Allergan/Inspire)	NF	ketorolac tromethamine 0.5% (generics)(Acular [®] - Allergan)	F	ketotifen fumarate 0.025% (generics)	F	lodoxamide tromethamine 0.1% (Alomide [®] -Alcon)	NF	loteprednol etabonate 0.2% (Alrex [®] - Bausch & Lomb)	NF	nedocromil sodium 2% (Alocril [®] - Allergan)	NF	olopatadine hydrochloride 0.1% (Patanol [®] - Alcon)	NF	olopatadine hydrochloride 0.2% (Pataday [®] - Alcon)	NF	pemirolast potassium 0.1% (Alamast [®] -Vistakon)	NF	<p>DECISION: Retain current formulary status for all ophthalmic anti-allergics.</p>
alcaftadine (Lastacaft [®] - Allergan)	NF																													
azelastine hydrochloride 0.05% (generics)	NF																													
bepotastine besilate 1.5% (Bepreve [®] -ISTA Pharmaceuticals)	NF																													
cromolyn sodium 4% (generics)	F																													
emedastine difumarate 0.05% (Emadine [®] - Alcon)	NF																													
epinastine hydrochloride 0.05% (Elestat [®] -Allergan/Inspire)	NF																													
ketorolac tromethamine 0.5% (generics)(Acular [®] - Allergan)	F																													
ketotifen fumarate 0.025% (generics)	F																													
lodoxamide tromethamine 0.1% (Alomide [®] -Alcon)	NF																													
loteprednol etabonate 0.2% (Alrex [®] - Bausch & Lomb)	NF																													
nedocromil sodium 2% (Alocril [®] - Allergan)	NF																													
olopatadine hydrochloride 0.1% (Patanol [®] - Alcon)	NF																													
olopatadine hydrochloride 0.2% (Pataday [®] - Alcon)	NF																													
pemirolast potassium 0.1% (Alamast [®] -Vistakon)	NF																													
	<p>Ophthalmic Antibiotics</p>																													

	<table border="1"> <tr><td>azithromycin (AzaSite® - Inspire)</td><td>NF</td></tr> <tr><td>bacitracin zinc ointment - generics</td><td>F</td></tr> <tr><td>bacitracin zinc/polymyxin B sulfate ointment - generics</td><td>F</td></tr> <tr><td>bacitracin zinc/neomycin/polymyxin B sulfate ointment -generics</td><td>F</td></tr> <tr><td>besifloxacin (Besivance® - Bausch Lomb)</td><td>NF</td></tr> <tr><td>ciprofloxacin ointment (Ciloxan® – Alcon)</td><td>NF</td></tr> <tr><td>ciprofloxacin solution - generics</td><td>F</td></tr> <tr><td>erythromycin ointment - generics</td><td>F</td></tr> <tr><td>gatifloxacin solution (Zymar® – Allergan)</td><td>NF</td></tr> <tr><td>gentamicin solution/ointment - generics</td><td>F</td></tr> <tr><td>levofloxacin solution (Quixin® – Santen)</td><td>NF</td></tr> <tr><td>moxifloxacin solution (Vigamox®, Moxeza® – Alcon)</td><td>NF</td></tr> <tr><td>neosporin/polymyxin B sulfate/gramicidin solution - generics</td><td>F</td></tr> <tr><td>ofloxacin solution -generics</td><td>F</td></tr> <tr><td>sodium sulfacetamide solution/ointment - generics</td><td>F</td></tr> <tr><td>tobramycin ointment (Tobrex® – Alcon)</td><td>F</td></tr> <tr><td>tobramycin solution - generics</td><td>F</td></tr> <tr><td>trimethoprim sulfate/polymyxin B sulfate solution - generics</td><td>F</td></tr> </table>	azithromycin (AzaSite® - Inspire)	NF	bacitracin zinc ointment - generics	F	bacitracin zinc/polymyxin B sulfate ointment - generics	F	bacitracin zinc/neomycin/polymyxin B sulfate ointment -generics	F	besifloxacin (Besivance® - Bausch Lomb)	NF	ciprofloxacin ointment (Ciloxan® – Alcon)	NF	ciprofloxacin solution - generics	F	erythromycin ointment - generics	F	gatifloxacin solution (Zymar® – Allergan)	NF	gentamicin solution/ointment - generics	F	levofloxacin solution (Quixin® – Santen)	NF	moxifloxacin solution (Vigamox®, Moxeza® – Alcon)	NF	neosporin/polymyxin B sulfate/gramicidin solution - generics	F	ofloxacin solution -generics	F	sodium sulfacetamide solution/ointment - generics	F	tobramycin ointment (Tobrex® – Alcon)	F	tobramycin solution - generics	F	trimethoprim sulfate/polymyxin B sulfate solution - generics	F	<p>DECISION:</p> <p>Retain current formulary status for all ophthalmic antibiotics.</p>
azithromycin (AzaSite® - Inspire)	NF																																					
bacitracin zinc ointment - generics	F																																					
bacitracin zinc/polymyxin B sulfate ointment - generics	F																																					
bacitracin zinc/neomycin/polymyxin B sulfate ointment -generics	F																																					
besifloxacin (Besivance® - Bausch Lomb)	NF																																					
ciprofloxacin ointment (Ciloxan® – Alcon)	NF																																					
ciprofloxacin solution - generics	F																																					
erythromycin ointment - generics	F																																					
gatifloxacin solution (Zymar® – Allergan)	NF																																					
gentamicin solution/ointment - generics	F																																					
levofloxacin solution (Quixin® – Santen)	NF																																					
moxifloxacin solution (Vigamox®, Moxeza® – Alcon)	NF																																					
neosporin/polymyxin B sulfate/gramicidin solution - generics	F																																					
ofloxacin solution -generics	F																																					
sodium sulfacetamide solution/ointment - generics	F																																					
tobramycin ointment (Tobrex® – Alcon)	F																																					
tobramycin solution - generics	F																																					
trimethoprim sulfate/polymyxin B sulfate solution - generics	F																																					
	<p>Ophthalmic NSAIDS</p> <table border="1"> <tr><td>bromfenac 0.07% ophthalmic solution (Prolensa® – Bausch & Lomb)</td><td>NF</td></tr> <tr><td>bromfenac 0.09% ophthalmic solution (generics)(Bromday® – Bausch & Lomb)</td><td>NF</td></tr> <tr><td>diclofenac sodium 0.1% ophthalmic solution (generics)(Voltaren Ophthalmic® – Novartis)</td><td>F</td></tr> <tr><td>ketorolac tromethamine 0.4% (generics)(Acular LS® -Allergan)</td><td>F</td></tr> <tr><td>ketorolac tromethamine 0.45% PF (Acuvail® -Allergan)</td><td>NF</td></tr> <tr><td>ketorolac tromethamine 0.5% (generics)(Acular® -Allergan)</td><td>F</td></tr> </table>	bromfenac 0.07% ophthalmic solution (Prolensa® – Bausch & Lomb)	NF	bromfenac 0.09% ophthalmic solution (generics)(Bromday® – Bausch & Lomb)	NF	diclofenac sodium 0.1% ophthalmic solution (generics)(Voltaren Ophthalmic® – Novartis)	F	ketorolac tromethamine 0.4% (generics)(Acular LS® -Allergan)	F	ketorolac tromethamine 0.45% PF (Acuvail® -Allergan)	NF	ketorolac tromethamine 0.5% (generics)(Acular® -Allergan)	F	<p>Recommendation</p> <p>Retain current formulary status for all ophthalmic NSAIDS.</p>																								
bromfenac 0.07% ophthalmic solution (Prolensa® – Bausch & Lomb)	NF																																					
bromfenac 0.09% ophthalmic solution (generics)(Bromday® – Bausch & Lomb)	NF																																					
diclofenac sodium 0.1% ophthalmic solution (generics)(Voltaren Ophthalmic® – Novartis)	F																																					
ketorolac tromethamine 0.4% (generics)(Acular LS® -Allergan)	F																																					
ketorolac tromethamine 0.45% PF (Acuvail® -Allergan)	NF																																					
ketorolac tromethamine 0.5% (generics)(Acular® -Allergan)	F																																					

	nepafenac 0.1% ophthalmic suspension (Nevanac [®] – Alcon)	NF	
	nepafenac 0.07% ophthalmic suspension (Ilevro [®] – Bausch & Lomb)	NF	
	Ophthalmic Prostaglandin Analogues		DECISION: Retain current formulary status of all ophthalmic prostaglandin analogues.
	bimatoprost 0.03% ophthalmic solution (Lumigan– Allergan)	NF	
	latanoprost 0.005% ophthalmic solution (generics) (Xalatan ^{□□} - Upjohn)	F	
	tafluprost 0.0015% ophthalmic solution [preservative-free] (Zioptan– Merck)	NF	
	travoprost 0.004% ophthalmic solution [benzalkonium chloride free] (Travatan Z– Alcon)	F-PA	
	unoprostone isopropyl 0.15% ophthalmic solution (Rescula [®] – Sucampo)	NF	
	Nasal Steroids		DECISION: 1. Move Beconase to Formulary with Prior Authorization criteria for coverage for post-surgical polyps. 2. Retain current formulary status for all other nasal steroids.
	beclomethasone dipropionate monohydrate nasal spray (Beconase [®] AQ – GlaxoSmithKline)	NF	
	budesonide nasal spray (generics)	NF	
	ciclesonide nasal spray (Omnaris [®] /Zetonna [®] – Sunovion)	NF	
	flunisolide nasal spray (generics)	F	
	fluticasone furoate nasal spray (Veramyst [®] – GlaxoSmithKline)	NF	
	fluticasone propionate nasal spray (generics)	F	
	mometasone nasal spray (Nasonex [®] – Schering-Plough)	NF	
	triamcinolone acetonide nasal spray (Nasacort [®] AQ and generics – SanofiAventis)	F-PA	
	azelastine hydrochloride and fluticasone propionate nasal spray (Dymista [®] – MEDA)	F-PA	
	beclomethasone dipropionate nasal spray (Qnasl [®] – Teva)	NF	
	Acne Vulgaris		DECISION: Retain current formulary

	adapalene gel (generics)	NF	status for all acne vulgaris
	adapalene cream (generics)	F	
	adapalene/benzoyl peroxide (Epiduo [®] – Galderma)	NF	
	azelaic acid cream (Azelex [®] – Allergan)	NF	
	azelaic acid gel (Finacea [®] - Bayer)	NF	
	benzoyl peroxide (generics)	F	
	benzoyl peroxide/erythromycin (generics)	F	
	benzoyl peroxide/sulfur (generics)	F	
	clindamycin phosphate and benzoyl peroxide (generics)	NF	
	clindamycin phosphate 1.2% and benzoyl peroxide 2.5% (Acanya [®] – Valeant)	NF	
	clindamycin phosphate and tretinoin gel (Ziana [®] – Valeant)	NF	
	clindamycin topical (generics)	F	
	dapsone topical (Aczone [®] – Allergan)	NF	
	erythromycin topical (generics)	F	
	sulfacetamide (generics)	F	
	tazarotene (Tazorac [®] – Allergan)	NF	
	tretinoin cream & gel (generics)	F	
	tretinoin microspheres (generics)	NF	